VEXAS SYNDROME – A NEW CHALLENGE AT THE INTERFACE OF RHEUMATOLOGY AND HEMATOLOGY: A REVIEW PAPER
Authors:
- Joanna KłosowskaJKJoanna Kłosowska
- Piotr ŚwierczekPŚPiotr Świerczek
- Małgorzata ZachMZMałgorzata Zach
- Karolina BłądzińskaKBKarolina Błądzińska
- Maciej BłądzińskiMBMaciej Błądziński
- Kacper SzelągKSKacper Szeląg
- Antoni KujawskiAKAntoni Kujawski
- Paula FoltaPFPaula Folta
- Anna OpalińskaAOAnna Opalińska
- Cezary LubasCLCezary Lubas
Open Access
- 16 September 2025
- journal article
- review article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(47))
Abstract
Research Objectives: This review summarizes current knowledge on VEXAS syndrome—its genetics, pathophysiology, symptoms, diagnosis, treatment, and prognosis—highlighting its clinical relevance. Methods: A focused literature review was conducted using PubMed and Google Scholar, emphasizing recent studies and relevant keywords related to VEXAS syndrome. Key Findings: VEXAS syndrome (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) is a newly identified, rare autoinflammatory disease caused by a somatic mutation in the UBA1 gene. It occurs almost exclusively in men and combines treatment-resistant inflammatory symptoms with bone marrow dysplasia, posing diagnostic and therapeutic challenges. VEXAS has a non-specific clinical course, combining symptoms of autoinflammatory diseases (e.g., chondritis, fever, vasculitis) with hematologic features such as cytopenias, macrocytosis, and myelodysplastic syndromes (MDS). Diagnosis is often delayed and requires high clinical suspicion and genetic testing of bone marrow to detect UBA1 mutations. There are no standardized treatment protocols; therapy usually includes glucocorticosteroids, immunosuppressants, and targeted agents. Allogeneic bone marrow transplantation may be an option in selected patients. Conclusions: VEXAS syndrome lies at the intersection of rheumatology and hematology. Though recently discovered, its clinical importance is growing. Diagnosis demands a multidisciplinary approach and molecular testing. Further studies and patient registries are essential to improve care and understanding of the disease.Keywords
This publication has 29 references indexed in Scilit:
- VEXAS syndromeInternational Journal of Hematology, 2024
- VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulationNature Communications, 2024
- VEXAS syndrome: Clinical manifestations, diagnosis, and treatmentReumatología Clínica (English Edition), 2023
- VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and managementAmerican Journal of Hematology, 2023
- VEXAS Syndrome—ReviewGlobal Medical Genetics, 2023
- Autoimmune manifestations in VEXAS: Opportunities for integration and pitfalls to interpretationJournal of Allergy and Clinical Immunology, 2023
- Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical PopulationJAMA, 2023
- VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseasesInternal and Emergency Medicine, 2023
- VEXAS-SyndromZeitschrift für Rheumatologie, 2022
- Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory DiseaseNew England Journal of Medicine, 2020